Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, Sandro Pignata, Lucy Gilbert, Diego Kaen, M Jesús Rubio, Sophia Frentzas, Mario Beiner, Manuel Magallanes-Maciel, Laura Farrelly, Chel Hun Choi, Regina Berger, Christine Lee, Christof Vulsteke, Kosei Hasegawa, Elena Ioanna Braicu, Xiaohua Wu, Jodi McKenzie, John J Lee, Vicky Makker
International Journal of Gynecologic Cancer Jan 2022, 32 (1) 93-100; DOI: 10.1136/ijgc-2021-003017